In conclusion, we report here a potential therapeutic target PAX8 whose silencing in NSCLC cells promotes loss in viability and motility; most likely through the deprivation of essential signals from MET and RON RTKs. This evidence concerns the gene MST1R and non-small cell lung carcinoma.